MX2011003588A - Anticuerpos neutralizadores del virus del dengue y uso de los mismos. - Google Patents

Anticuerpos neutralizadores del virus del dengue y uso de los mismos.

Info

Publication number
MX2011003588A
MX2011003588A MX2011003588A MX2011003588A MX2011003588A MX 2011003588 A MX2011003588 A MX 2011003588A MX 2011003588 A MX2011003588 A MX 2011003588A MX 2011003588 A MX2011003588 A MX 2011003588A MX 2011003588 A MX2011003588 A MX 2011003588A
Authority
MX
Mexico
Prior art keywords
seq
antibody
antigen
amino acid
acid sequence
Prior art date
Application number
MX2011003588A
Other languages
English (en)
Spanish (es)
Inventor
Antonio Lanzavecchia
Original Assignee
Inst Research In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Research In Biomedicine filed Critical Inst Research In Biomedicine
Publication of MX2011003588A publication Critical patent/MX2011003588A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2011003588A 2008-10-13 2009-10-13 Anticuerpos neutralizadores del virus del dengue y uso de los mismos. MX2011003588A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10491108P 2008-10-13 2008-10-13
PCT/IB2009/007372 WO2010043977A2 (en) 2008-10-13 2009-10-13 Dengue virus neutralizing antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2011003588A true MX2011003588A (es) 2011-10-14

Family

ID=42102977

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011003588A MX2011003588A (es) 2008-10-13 2009-10-13 Anticuerpos neutralizadores del virus del dengue y uso de los mismos.

Country Status (10)

Country Link
US (1) US9073981B2 (enExample)
EP (1) EP2334700B1 (enExample)
JP (2) JP5814790B2 (enExample)
CN (2) CN102272155B (enExample)
AU (1) AU2009305113B2 (enExample)
BR (1) BRPI0914012B1 (enExample)
CA (1) CA2739551C (enExample)
MX (1) MX2011003588A (enExample)
NZ (1) NZ592054A (enExample)
WO (1) WO2010043977A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
ES2644236T3 (es) * 2010-12-14 2017-11-28 National University Of Singapore Anticuerpo humano monoclonal con especificidad para el virus Dengue serotipo 1 E proteína y usos de la misma
WO2013035345A2 (en) * 2011-09-09 2013-03-14 Osaka University Dengue-virus serotype neutralizing antibodies
WO2013173348A1 (en) * 2012-05-14 2013-11-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Cross-reactive antibodies against dengue virus and uses thereof
WO2014025546A2 (en) 2012-08-07 2014-02-13 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
WO2015089492A2 (en) * 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
JP7078350B2 (ja) 2013-10-28 2022-05-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｄｎａ抗体構築物及びその使用方法
KR20230156146A (ko) * 2012-12-13 2023-11-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｄｎａ 항체 작제물 및 그 이용 방법
JP6154126B2 (ja) * 2012-12-20 2017-06-28 功 宮崎 検査キットおよび検査方法
SG11201507359SA (en) 2013-03-15 2015-10-29 Dana Farber Cancer Inst Inc Flavivirus neutralizing antibodies and methods of use thereof
CN103396481B (zh) * 2013-07-18 2015-06-03 华南理工大学 一种二型登革热病毒ns1蛋白的重链单域抗体及其制备方法和应用
WO2015095511A2 (en) * 2013-12-20 2015-06-25 The Scripps Research Institute Functional antibodies that modulate cell death and related methods
CA2938590C (en) 2014-02-11 2023-10-17 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
SG10201807826XA (en) * 2014-02-11 2018-10-30 Massachusetts Inst Technology Novel full spectrum anti-dengue antibody
RS61000B1 (sr) * 2014-09-01 2020-11-30 Int Centre For Genetic Engineering And Biotechnology Vakcina
BR112017011556A2 (en) 2014-12-01 2018-03-06 The Trustees Of The University Of Pennsylvania methods for generating a synthetic antibody, preventing or treating a disease, treating a subject of pathogen infection and a subject with cancer, product, nucleic acid molecule, and composition.
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
SG11201707592TA (en) * 2015-03-17 2017-10-30 Agency Science Tech & Res A serotype cross-reactive, dengue neutralizing antibody and uses thereof
WO2017011495A1 (en) * 2015-07-14 2017-01-19 Vanderbilt University Engineered antibodies against dengue virus
JP7155009B2 (ja) 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
TWI769185B (zh) * 2016-10-27 2022-07-01 海樂源有限公司 登革熱類病毒顆粒、抗登革熱病毒抗體、及含其之組合物
US11249082B2 (en) 2016-10-29 2022-02-15 University Of Miami Zika virus assay systems
US20190324040A1 (en) * 2016-10-29 2019-10-24 University Of Miami Zika virus antibodies
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
KR102238183B1 (ko) 2018-05-04 2021-04-12 가톨릭대학교 산학협력단 유전자 합성을 통해 설계된 뎅기열 바이러스의 유전형 복합 ｎｓ１ 재조합 항원 및 대조군 유행성 플라비바이러스 유전형 복합 ns1 재조합 항원 풀
US11830582B2 (en) 2018-06-14 2023-11-28 University Of Miami Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
WO2020078568A1 (en) 2018-10-19 2020-04-23 Humabs Biomed Sa Antibodies and methods for treatment of lyssavirus infection
CN111320688B (zh) * 2018-12-17 2021-08-24 中国科学院天津工业生物技术研究所 一种黄病毒中和抗体、其制备方法及应用
KR102048812B1 (ko) * 2018-12-19 2019-11-26 주식회사 엠디헬스케어 뎅기 바이러스 ediii에 특이적으로 결합하는 dna 압타머 및 이의 용도
EP4153625A4 (en) * 2020-05-20 2024-09-25 The Trustees Of Columbia University In The City Of New York STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB819376A (en) 1956-10-20 1959-09-02 Colne Switchgear K & W Ltd Improvements in electro-magnetic overload units for electrical apparatus
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
US6300104B1 (en) 1997-06-19 2001-10-09 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
US7473424B2 (en) * 2003-01-31 2009-01-06 The Scripps Research Institute Anti-dengue virus antibodies and compositions
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
US7622113B2 (en) * 2003-12-08 2009-11-24 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
WO2009011941A2 (en) * 2007-04-04 2009-01-22 The Government Of U.S.A., As Represented By The Secretary, Departmetnt Of Health & Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region

Also Published As

Publication number Publication date
AU2009305113B2 (en) 2015-07-16
CN102272155A (zh) 2011-12-07
JP5814790B2 (ja) 2015-11-17
CA2739551C (en) 2019-03-05
AU2009305113A1 (en) 2010-04-22
EP2334700B1 (en) 2017-09-13
EP2334700A2 (en) 2011-06-22
WO2010043977A3 (en) 2010-09-30
CN102272155B (zh) 2018-05-25
CA2739551A1 (en) 2010-04-22
US20120020957A1 (en) 2012-01-26
WO2010043977A2 (en) 2010-04-22
JP2016020334A (ja) 2016-02-04
JP2012504955A (ja) 2012-03-01
CN108610416A (zh) 2018-10-02
BRPI0914012A2 (pt) 2021-02-23
BRPI0914012B1 (pt) 2022-02-15
US9073981B2 (en) 2015-07-07
NZ592054A (en) 2013-06-28
CN108610416B (zh) 2022-01-14

Similar Documents

Publication Publication Date Title
US9073981B2 (en) Dengue virus neutralizing antibodies and use thereof
CA2731686C (en) Neutralizing anti-influenza a virus antibodies and uses thereof
JP5710123B2 (ja) ヒトサイトメガロウイルス中和抗体およびその使用
EP2303923B1 (en) Human cytomegalovirus neutralising antibodies and use thereof
CN103717617B (zh) 中和抗甲型流感病毒抗体及其用途
HK1260890B (zh) 登革热病毒中和抗体及其用途
HK1260890A1 (zh) 登革热病毒中和抗体及其用途
HK1164898A (en) Dengue virus neutralizing antibodies and uses thereof
HK1164898B (en) Dengue virus neutralizing antibodies and uses thereof
JP2014087349A (ja) ヒトサイトメガロウイルス中和抗体およびその使用

Legal Events

Date Code Title Description
FG Grant or registration